Corticosteroid-independent inhibition of tumor necrosis factor production by the neuropeptide urocortin.

Urocortin (UCN) is a neuropeptide homologous with corticotropin-releasing factor (CRF), which has anti-inflammatory activities not all mediated by corticosteroids. In mice, UCN (1 microg/mouse sc) significantly reduced lipopolysaccharide (LPS)-induced serum tumor necrosis factor (TNF) and interleukin (IL)-1beta levels in vivo but did not affect serum IL-6. These effects were paralleled by a rise in corticosterone (CS) levels. Blockade of the CS increase by cyanoketone did not prevent TNF inhibition by UCN, suggesting the neuropeptide has anti-inflammatory mechanisms independent of the hypothalamus-pituitary-adrenal axis. In fact UCN had a direct inhibitory effect on LPS-induced TNF in rat Kupffer cells at concentrations between 10(-10) and 10(-16) M, and this effect was related to increased cAMP levels. However, the in vivo inhibition of LPS-induced IL-1beta by UCN was reversed by cyanoketone, indicating that the increase of endogenous glucocorticoids might be more important in IL-1beta inhibition than in TNF inhibition by UCN.

[1]  M. Feldmann,et al.  Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Correa,et al.  Modulation of the inflammatory response by corticotropin-releasing factor. , 1997, European journal of pharmacology.

[3]  J. M. Lipton,et al.  Anti-inflammatory actions of the neuroimmunomodulator α-MSH , 1997 .

[4]  G. Fantuzzi,et al.  Glucocorticoids as cytokine inhibitors: role in neuroendocrine control and therapy of inflammatory diseases , 1993, Mediators of inflammation.

[5]  J. Dave,et al.  Corticotropin-releasing factor binding to peripheral tissue and activation of the adenylate cyclase-adenosine 3',5'-monophosphate system. , 1985, Endocrinology.

[6]  A. Mantovani,et al.  Differential sensitivity of in vivo TNF and IL-6 production to modulation by anti-inflammatory drugs in mice. , 1992, International journal of immunopharmacology.

[7]  C. Donaldson,et al.  Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[8]  N. Ling,et al.  Stress and autoimmunity: the neuropeptides corticotropin-releasing factor and urocortin suppress encephalomyelitis via effects on both the hypothalamic-pituitary-adrenal axis and the immune system. , 1997, Journal of immunology.

[9]  B. Smedsrød,et al.  Preparation of Pure Hepatocytes and Reticuloendothelial Cells in High Yield From a Single Rat Liver by Means of Percoll Centrifugation and Selective Adherence , 1985, Journal of leukocyte biology.

[10]  G. Chrousos,et al.  The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. , 1995, The New England journal of medicine.

[11]  A. Lichtenstein,et al.  Corticotropin-releasing factor reduces lipopolysaccharide-induced pulmonary vascular leak. , 1994, Immunopharmacology and immunotoxicology.

[12]  R. Gerzer,et al.  Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells. , 1991, Immunology.

[13]  P. Ghezzi,et al.  Adrenalectomy sensitizes mice to the lethal effects of interleukin 1 and tumor necrosis factor , 1988, The Journal of experimental medicine.

[14]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[15]  D. Remick,et al.  In vivo biologic and immunohistochemical analysis of interleukin-1 alpha, beta and tumor necrosis factor during experimental endotoxemia. Kinetics, Kupffer cell expression, and glucocorticoid effects. , 1991, The American journal of pathology.

[16]  D. Goeddel,et al.  Human tumor necrosis factor. Production, purification, and characterization. , 1985, The Journal of biological chemistry.

[17]  W. Vale,et al.  Urocortin, a corticotropin-releasing factor-related mammalian peptide, inhibits edema due to thermal injury in rats. , 1996, European journal of pharmacology.

[18]  J. Vilček,et al.  Synthesis of interleukin 6 (interferon-beta 2/B cell stimulatory factor 2) in human fibroblasts is triggered by an increase in intracellular cyclic AMP. , 1988, The Journal of biological chemistry.

[19]  A. Mantovani,et al.  IL-1 stimulates IL-6 production in endothelial cells. , 1989, Journal of immunology.

[20]  N. Ling,et al.  Immunosuppressive phenotype of corticotropin-releasing factor transgenic mice is reversed by adrenalectomy. , 1997, Cellular immunology.

[21]  David Lovejoy,et al.  Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor , 1995, Nature.

[22]  M. Brownstein,et al.  In vivo corticotropin-releasing factor-induced secretion of adrenocorticotropin, beta-endorphin, and corticosterone. , 1982, Endocrinology.

[23]  D. Yarnall,et al.  Differential regulation of human monocyte-derived TNF alpha and IL-1 beta by type IV cAMP-phosphodiesterase (cAMP-PDE) inhibitors. , 1995, The Journal of pharmacology and experimental therapeutics.

[24]  F. Holsboer,et al.  Long-term intracerebroventricular corticotropin-releasing hormone administration induces distinct changes in rat splenocyte activation and cytokine expression. , 1995, Endocrinology.

[25]  D. Gemsa,et al.  Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. , 1988, Journal of immunology.

[26]  G. Battaglia,et al.  Functional corticotropin-releasing factor (CRF) receptors in mouse spleen: Evidence from adenylate cyclase studies , 1989, Peptides.

[27]  R. Clark,et al.  An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis , 1990, The Journal of experimental medicine.

[28]  J. Bertrand,et al.  Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. , 1996, Critical care medicine.

[29]  E. F. Smith,et al.  Characterization of cAMP-dependent inhibition of LPS-induced TNF alpha production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. , 1994, International journal of immunopharmacology.

[30]  J. Tian,et al.  Protective actions of corticotropin-releasing factor on thermal injury to rat pawskin. , 1988, The Journal of pharmacology and experimental therapeutics.

[31]  T. Lovenberg,et al.  CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. , 1995, Endocrinology.

[32]  K. Molnar-Kimber,et al.  Differential regulation of TNF-α and IL-1β production from endotoxin stimulated human monocytes by phosphodiesterase inhibitors , 1992, Mediators of inflammation.